Episode Player
AUDEARA LTD (AUA) - Audeara’s CEO Explains The Strategy Behind Q3 Growth
ASX BRIEFS
A kid can’t learn well if the world sounds muffled, painful, or simply out of reach. We’re joined by Dr James Fielding, Managing Director and CEO of Audeara Limited, to talk through a pivotal stretch for this ASX-listed hearing health technology and audio technology company, following strong Q3 FY26 results and a growing global footprint.
We start with what Audeara actually builds: hearing health tech solutions sold as Audeara-branded hardware, plus the AUA Technology platform that can power other brands. James then explains the significance of an exclusive agreement with ShokzHear, the global leader in bone conduction listening devices. The goal is practical and urgent: create an optimised listening option for children dealing with chronic ear infections, particularly in regional and remote communities where in-ear devices can be uncomfortable or unusable. We also discuss just how widespread classroom listening issues can be and what better audio access could mean for learning outcomes.
From there we dig into the numbers investors care about, including back-to-back positive net operating cash flow and accelerating Australian wholesale revenue, supported by closer partner execution with audiology groups such as Amplifon. We finish with Audeara’s Auracast™ momentum, the Clinico partnership in Taiwan, and the BT-03 Audio Broadcaster rollout into environments like universities, hospitals, government buildings, and even sports bars where people can choose exactly what they want to hear.
If you’re tracking ASX small caps, medtech commercialisation, Auracast, bone conduction, or accessible audio, hit subscribe, share this with a mate, and leave a review to help more people find the show.
